Worth reading
38Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
684814
¥Wording
Definitive
How definitive the wording is.Announced details
Global All-Biology Genome Equity Fund (Annual Accounting Type)
Applicable field (uses covered by this announcement)
HealthcareGene therapies, including cancer treatmentsFoodEnvironment
Launch dateSales commenced in December 2020 (actual)
What the company reported numerically
Usage history
This was the 4th donation, bringing the cumulative amount to ¥5,366,802
Relationship between the counterparty and the company
OKASAN SECURITIES GROUP INC.8609
Relationship with the Company
Okasan Securities Co., Ltd. sells the fund and donates part of the trust fees earned from it.
CounterpartyMultiple rare disease support organizations
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Global All-Biology Genome Equity Fund (Annual Accounting Type) |
| Counterparty | Multiple rare disease support organizations |
| Relationship with the Company | Okasan Securities Co., Ltd. sells the fund and donates part of the trust fees earned from it. |
| Launch date | Sales commenced in December 2020 (actual) |
| Applicable area | Healthcare, Gene therapies, including cancer treatments, Food, Environment |
| Usage history | This was the 4th donation, bringing the cumulative amount to ¥5,366,802 |
Items this document does not state (12)
Counterparty overviewContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsImpact on Business PerformanceSource
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To support rare disease organizations and promote innovation, including the development of new gene therapies such as cancer treatments.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.